Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide
Alkylating agents have long played a central role in the adjuvant therapy of glioblastoma (GBM). More recently, inclusion of temozolomide (TMZ), an orally administered methylating agent with low systemic toxicity, during and after radiotherapy has markedly improved survival. Extensive in vitro and i...
| Main Authors: | , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Frontiers Media S.A.
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515961/ |